{"id":"NCT01183858","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)","officialTitle":"A Prospective, Double-blind Randomized Phase III Study of 300 mg Versus 150 mg Erlotinib in Current Smokers With Locally Advanced or Metastatic NSCLC in Second-line Setting After Failure on Chemotherapy (CURRENTS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2013-10","completion":"2014-02","firstPosted":"2010-08-18","resultsPosted":"2015-02-23","lastUpdate":"2015-08-19"},"enrollment":315,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Erlotinib [Tarceva]","otherNames":["Tarceva"]}],"arms":[{"label":"Erlotinib 150 mg","type":"EXPERIMENTAL"},{"label":"Erlotinib 300 mg","type":"EXPERIMENTAL"}],"summary":"This prospective, double-blind, randomized study will evaluate the safety and efficacy of two dose levels of erlotinib \\[Tarceva\\] on progression-free survival, response and disease control rates and overall survival in patients with advanced or metastatic non-small cell lung cancer (NSCLC) after failure of first-line platinum-based chemotherapy. Patients must be current smokers and not intending to stop smoking during the study. Patients will be randomized to receive either 150 mg or 300 mg of study drug as single daily oral doses. Treatment will continue until disease progression.","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 Months)","effectByArm":[{"arm":"Erlotinib 150 mg","deltaMin":6.86,"sd":null},{"arm":"Erlotinib 300 mg","deltaMin":7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.671"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":63,"countries":["China","Denmark","Egypt","France","Germany","Netherlands","Spain","Switzerland","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":154},"commonTop":["Rash","Diarrhoea","Decreased appetite","Fatigue","Dyspnoea"]}}